Evidence map›Paper›PMID 38281066›Full record

ArticleNucleus (Austin, Tex.)2024

The perinucleolar compartment: structure, function, and utility in anti-cancer drug development.

Eugene V Makeyev, Sui Huang

Open access · goldAbstract read
In one paragraph

Article in Nucleus (Austin, Tex.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Eugene V MakeyevCentre for Developmental Neurobiology, King's College London, London, UK.ORCID 0000-0001-6034-6896
Sui HuangDepartment of Cell and Developmental Biology, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-2400-4319
King's College London · GBNorthwestern University · US

Funding

The role of the nucleolus in human genome organization in normal and disease statesU01CA260699 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FOLTZ, DANIEL RICHARD, HUANG, SUI · 2020 to 2024
$3.3M
Phenotypic marker-guided development of selective antimetastasis therapeutic leadsR01CA269967 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Kevin J. Frankowski, Sui HUANG · 2022 to 2026
$3.2M
NCI NIH HHS R01 CA269967NCI NIH HHS U01 CA260699
6 · The paper itself

Abstract

The perinucleolar compartment (PNC) was initially identified as a nuclear structure enriched for the polypyrimidine tract-binding protein. Since then, the PNC has been implicated in carcinogenesis. The prevalence of this compartment is positively correlated with disease progression in various types of cancer, and its expression in primary tumors is linked to worse patient outcomes. Using the PNC as a surrogate marker for anti-cancer drug efficacy has led to the development of a clinical candidate for anti-metastasis therapies. The PNC is a multicomponent nuclear body situated at the periphery of the nucleolus. Thus far, several non-coding RNAs and RNA-binding proteins have been identified as the PNC components. Here, we summarize the current understanding of the structure and function of the PNC, as well as its recurrent links to cancer progression and metastasis.

Indexed as

Antineoplastic AgentsNeoplasmsCell NucleolusCell NucleusHumansRNA-Binding ProteinsAntineoplastic AgentsRNA-Binding ProteinsAnti-cancer drug developmentnon-coding RNAnucleolusPNCRNA binding proteins

Identifiers

PMID38281066
PMCPMC10824145
OpenAlexW4391294086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.